GGrantIndex
Sort

261,768 grants matching gene therapy

Development of an intravenous CB1 antagonist for acute cannabinoid intoxication and cannabis hyperemesis syndrome

$994,300
Kenneth Cundy · Anebulo Pharmaceuticals, Inc. · U01 · FY2025 · DA

A novel immuno-oncolytic viral therapy for the treatment of non-small cell lung carcinoma

$994,294
Stephen H Thorne · Western Oncolytics, Ltd · R44 · FY2020 · CA

Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

$994,272
Ryan David Wuebbles · Strykagen Corporation · R44 · FY2024 · OD

Neurocognitive Aging: Epigenetic Dynamics, Plasticity and Network Contributions

$994,236
Peter R Rapp · National Institute On Aging · ZIA · FY2015 · AG

Quick and Accurate Measurements of HIV Broadly Neutralizing Antibody Susceptibility

$994,203
Masahiro Yamashita · Columbia University Health Sciences · R61 · FY2025 · AI

A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance

$994,179
Neil A Fanger · Virtici, Llc · R44 · FY2021 · AI

ExRNA Mouse Core

$994,078
Michael T McManus · University Of California, San Francisco · U19 · FY2017 · CA

Novel Diagnostic Sequencing System for HIV Resistance Testing

$994,055
Jerzy Olejnik · Intelligent Bio-Systems, Inc. · R44 · FY2011 · AI

A platform for high-throughput production of targeting systems for cell-type-specific transgene expression in wild-type animals

$993,992
Ian R Wickersham · Massachusetts Institute Of Technology · R01 · FY2016 · MH

Optimization of an in vivo base editing strategy to treat SOD1-linked ALS

$993,968
Thomas Gaj · University Of Illinois At Urbana-Champaign · U01 · FY2025 · NS

Aerosolized Vitamin A: Developing a Prevention for Hyperoxic Lung Injury and Bronchopulmonary Dysplasia, with Focus on Neonatal Lung Maturation

$993,934
Craig Gelfand · Advent Therapeutics, Inc. · R44 · FY2024 · HL

Lentiviral Gene Therapy for Wiskott-Aldrich Syndrome

$993,911
David J Rawlings · Seattle Children'S Hospital · R01 · FY2009 · AI

Discovery of B. pseudomallei therapeutics for Biodefense

$993,879
Donald T Moir · Microbiotix, Inc · R44 · FY2006 · AI

STING Activators as Therapy for Cancer

$993,879
Glen N Barber · Stinginn, Llc · R42 · FY2023 · CA

Novel strategy to block AAV neutralizing antibody activity

$993,865
Charles H Askew · Nabgen, Inc. · R42 · FY2025 · TR

Improving marginal allograft outcomes through cell junction stabilization in transplantation

$993,803
Christina Grek · Xequel Bio, Inc. · R44 · FY2021 · DK

Models for Vision Research

$993,798
Patsy M Nishina · Jackson Laboratory · R01 · FY2010 · EY

HIV Persistence During Suppressive Antiretroviral Therapy

$993,764
Frank Maldarelli · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana

$993,747
Roger L Shapiro · Harvard School Of Public Health · U01 · FY2023 · AI

Demystifying Disorders of Bicistronic Calcium Channel Genes

$993,747
Christopher Manuel Gomez · University Of Chicago · R35 · FY2020 · NS

The differential diagnosis and treatment of Cushing's syndrome

$993,704
Lynnette Nieman · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK

Molecular pathogenesis and therapy innovation for Merkel cell carcinoma

$993,703
Isaac Brownell · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2024 · AR

A polymeric biomaterial-based vaccine utilizing immunomodulatory agents and antigen for the amelioration of type 1 diabetes.

$993,629
Benjamin Michael Looney · Inspira Therapeutics, Inc. · R44 · FY2021 · DK

H. pylori-Induced Inflammation and gastric cancer

$993,628
Richard M Peek · Vanderbilt University Medical Center · P01 · FY2016 · CA

UCLA Pharmacogenetics and Pharmacogenomics Research Grp*

$993,608
University Of California Los Angeles · U01 · FY2003 · GM